Current Report Filing (8-k)
04 Janeiro 2022 - 6:25PM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-12-31
2021-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December
31, 2021
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area
code: (858) 997-2400
(Former name or Former Address, if Changed Since Last
Report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On December 31, 2021, Adamis Pharmaceuticals
Corporation (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”)
notifying the Company that for 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00
per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Marketplace
Rule 5550(a)(2). This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock.
In accordance with Nasdaq Marketplace Rule
5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until June 29, 2022, to regain
compliance. If at any time before June 29, 2022, the bid price of the Company’s common stock closes at or above $1.00 per
share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved
compliance with the minimum bid price requirement, and the matter would be resolved. The notice letter also disclosed that if the
Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance
period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of
publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price
requirement, and would need to provide written notice of a plan to cure the deficiency during the second compliance period. If the
Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain
compliance. However, if it appears to the staff of Nasdaq that the Company will not be able to cure the deficiency, or if the
Company is otherwise not eligible, the staff would notify the Company that it will not be granted additional 180 days for compliance
and will be subject to delisting at that time. In the event of such notification, the Company may appeal the staff’s
determination to delist its securities, but there can be no assurance that any such appeal would be successful. The Company intends
to monitor the closing bid price for its common stock and will consider available strategies in an effort to satisfy the minimum bid
price requirement. However, there are no assurances that the Company will be able to regain compliance with the minimum bid price
requirements or will otherwise be in compliance with other Nasdaq listing rules.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: January 4, 2022
|
By:
|
/s/ David C. Benedicto
|
|
Name:
|
David C. Benedicto
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024